Pharmacogenomic application of the haptoglobin genotype in the treatment of HDL dysfunction

Review

(2589) Views  (1026) Full article downloads

Authors: Avery Schwartz, Shany Blum, Rabea Asleh, Mordechai Pollak, Shiri Kalet-Litman, Andrew P Levy

Published Date February 2009 Volume 2009:2 Pages 1 - 8

DOI: http://dx.doi.org/10.2147/PGPM.S4608

Avery Schwartz, Shany Blum, Rabea Asleh, Mordechai Pollak, Shiri Kalet-Litman, Andrew P Levy

Department of Anatomy and Cell Biology, Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel

Abstract: An emerging paradigm of research has suggested that in the setting of diabetes mellitus (DM) the quality or function of high-density lipoprotein (HDL) may be a determinant of cardiovascular disease risk. Specific structural modifications of HDL protein and lipid components, resulting from oxidative modification, have been proposed to mediate HDL’s loss of the ability to promote cholesterol efflux (reverse cholesterol transport), serve as an antioxidant and anti-inflammatory agent. Therefore, inhibiting HDL oxidative modification would be expected to improve its function and provide cardioprotection. Nevertheless, antioxidant strategies to reduce cardiovascular events from atherosclerosis in DM have failed. It has been proposed that this failure may have been due to the inadequate nature of patient selection. High dose antioxidant therapy may only provide benefit to a subset of DM individuals with oxidatively modified HDL. We will review evidence that haptoglobin (Hp) identifies such individuals who can be successfully treated with vitamin E. These data will suggest that a pharmacogenomic approach utilizing the Hp genotype may be useful in identifying individuals who will benefit from antioxidant therapy.

Keywords: diabetes, HDL, vitamin E, cardiovascular disease, oxidation